Edition:
United States

Dr.Reddy's Laboratories Ltd (REDY.BO)

REDY.BO on Bombay Stock Exchange

2,456.65INR
22 Sep 2017
Change (% chg)

Rs-29.80 (-1.20%)
Prev Close
Rs2,486.45
Open
Rs2,509.00
Day's High
Rs2,528.60
Day's Low
Rs2,445.65
Volume
137,301
Avg. Vol
59,084
52-wk High
Rs3,394.95
52-wk Low
Rs1,901.65

Latest Key Developments (Source: Significant Developments)

Dr. Reddy's Labs launches Ezetimibe and Simvastatin tablets in U.S. market
Thursday, 27 Apr 2017 12:37am EDT 

April 27 (Reuters) - Dr.Reddy's Laboratories Ltd :Says launch of Ezetimibe and Simvastatin tablets in U.S. market.  Full Article

Dr. Reddy's Labs, Integra Lifesciences sign deal to market Duragen products in India
Monday, 27 Mar 2017 03:02am EDT 

Dr.Reddy's Laboratories Ltd : Co, Integra Lifesciences enter agreement to market, distribute Duragen plus and suturable duragen dural regeneration in India .Says to market, distribute duragen plus and suturable duragen dural renegration matrices for use in India.  Full Article

Dr Reddys says preparing response on observations received from US FDA
Tuesday, 21 Mar 2017 02:59am EDT 

Dr.Reddy's Laboratories Ltd : Clarifies on news item "US FDA finds repeat observations from 2015 warning letter. Failed to maintain complete data to ensure compliance." .Says preparing response and will submit it to FDA.  Full Article

Cytosorbents Corp enters into a partnership with Dr. Reddy's laboratories
Thursday, 16 Mar 2017 07:00am EDT 

Cytosorbents Corp : Have entered into a partnership with Dr. Reddy's laboratories ltd for South African market . Dr. Reddy's has exclusive rights to distribute Cytosorb for intensive care, cardiac surgery, other hospital applications in South Africa . Multi-year agreement is subject to annual minimum purchases of Cytosorb to maintain exclusivity .Financial terms of this agreement have not been disclosed.  Full Article

Dr.Reddy's Labs gets form 483 with 3 observations from USFDA for audit of Miryalaguda plant
Tuesday, 21 Feb 2017 08:10am EST 

Dr.Reddy's Laboratories Ltd : Says the audit of API manufacturing plant at Miryalaguda, by the US FDA, has been completed on February 21, 2017 .Co has been issued a form 483 with three observations.  Full Article

Dr.Reddy's Labs says co not served with legal papers in matter as in Mezzion's press release
Friday, 27 Jan 2017 04:57am EST 

Dr.Reddy's Laboratories Ltd : Dr.Reddy's Laboratories clarifies on news item "Korean biotech firm Mezzion Pharma files suit against Dr Reddy's laboratories." .Dr.Reddy's Laboratories Ltd says co not been served with legal papers or process in matter as in Mezzion's press release.  Full Article

Dr. Reddy's Labs says U.S. FDA re-audit of co's plants part of "usual activity"
Thursday, 12 Jan 2017 03:13am EST 

Dr.Reddy's Laboratories Ltd : Clarifies on news item "FDA to re-audit three Dr.Reddy's labs plants" .Says believes that schedule of audit by USFDA is usual activity.  Full Article

Sucampo Q3 adjusted EPS $0.28
Wednesday, 9 Nov 2016 06:30am EST 

Sucampo Pharmaceuticals Inc : Sucampo pharmaceuticals inc - company raises 2016 guidance and provides preliminary 2017 guidance . Sucampo pharmaceuticals inc - announces settlement with dr. Reddy's laboratories for amitiza . Sees 2016 total revenue $220.0 million to $225.0 million . Fy2016 earnings per share view $1.03, revenue view $205.7 million -- Thomson Reuters I/B/E/S . Sees 2016 adjusted ebitda $110.0 million to $115.0 million . Sucampo pharmaceuticals - phase 3 trial of amitiza in pediatric functional constipation in children 6-17 yrs of age did not achieve primary endpoint . Sucampo pharmaceuticals inc- completed a settlement and license agreement with dr. Reddy's laboratories, ltd. And certain of its affiliates . Sucampo pharmaceuticals - agreement resolves patent litigation in united states related to sucampo's amitiza 8 mcg and 24 mcg soft gelatin capsules . Sucampo pharmaceuticals - agreement provides for an entry date more than six years from wednesday and profit sharing on product sales by dr. Reddy's . Sucampo reports third quarter 2016 financial results . Q3 adjusted earnings per share $0.28 . Q3 gaap earnings per share $0.19 . Q3 revenue $57.9 million versus i/b/e/s view $51.4 million . Q3 earnings per share view $0.27 -- Thomson Reuters I/B/E/S .Sees fy 2016 adjusted earnings per share $1.20 to $1.25.  Full Article

Dr.Reddy's Labs exec says co has addressed all FDA requirements on warning letters
Tuesday, 25 Oct 2016 09:33am EDT 

Dr.Reddy's Laboratories Ltd : Exec says have addressed all FDA requirements on warning letters . Exec says pricing erosion has become a part of U.S. business model Further company coverage: [REDY.NS] (Bengaluru newsroom) ((ReutersIndia.snapping@thomsonreuters.com ;)).  Full Article

Dr.Reddy's Labs announces entry into Columbia
Friday, 7 Oct 2016 09:11am EDT 

Dr.Reddy's Laboratories Ltd :Announces entry into Columbia.  Full Article

BRIEF-Dr.Reddy's Labs says FDA completes ‍audit of co's Telangana facilities with no observations​

* FDA completes ‍audit of co's Telangana custom pharmaceutical services facility, technology development centre with no observations​ Source text: http://bit.ly/2hhsmbf Further company coverage: